174 related articles for article (PubMed ID: 37644332)
1. Targeting EZH2 regulates the biological characteristics of glioma stem cells via the Notch1 pathway.
Zhao G; Deng Z; Li X; Wang H; Chen G; Feng M; Zhou Y
Exp Brain Res; 2023 Oct; 241(10):2409-2418. PubMed ID: 37644332
[TBL] [Abstract][Full Text] [Related]
2. Dual inhibition of Src and PLK1 regulate stemness and induce apoptosis through Notch1-SOX2 signaling in EGFRvIII positive glioma stem cells (GSCs).
Li X; Tao Z; Wang H; Deng Z; Zhou Y; Du Z
Exp Cell Res; 2020 Nov; 396(1):112261. PubMed ID: 32896567
[TBL] [Abstract][Full Text] [Related]
3. Enhancer of Zeste 2 (EZH2) is up-regulated in malignant gliomas and in glioma stem-like cells.
Orzan F; Pellegatta S; Poliani PL; Pisati F; Caldera V; Menghi F; Kapetis D; Marras C; Schiffer D; Finocchiaro G
Neuropathol Appl Neurobiol; 2011 Jun; 37(4):381-94. PubMed ID: 20946108
[TBL] [Abstract][Full Text] [Related]
4. Effects of Enhancer of Zeste Homolog 2 (EZH2) Expression on Brain Glioma Cell Proliferation and Tumorigenesis.
Cheng T; Xu Y
Med Sci Monit; 2018 Oct; 24():7249-7255. PubMed ID: 30305602
[TBL] [Abstract][Full Text] [Related]
5. Mesenchymal stem cell-derived exosomal microRNA-133b suppresses glioma progression via Wnt/β-catenin signaling pathway by targeting EZH2.
Xu H; Zhao G; Zhang Y; Jiang H; Wang W; Zhao D; Hong J; Yu H; Qi L
Stem Cell Res Ther; 2019 Dec; 10(1):381. PubMed ID: 31842978
[TBL] [Abstract][Full Text] [Related]
6. n-Butylidenephthalide Regulated Tumor Stem Cell Genes EZH2/AXL and Reduced Its Migration and Invasion in Glioblastoma.
Yen SY; Chuang HM; Huang MH; Lin SZ; Chiou TW; Harn HJ
Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28208648
[TBL] [Abstract][Full Text] [Related]
7. Melatonin Inhibits Glioblastoma Stem-like cells through Suppression of EZH2-NOTCH1 Signaling Axis.
Zheng X; Pang B; Gu G; Gao T; Zhang R; Pang Q; Liu Q
Int J Biol Sci; 2017; 13(2):245-253. PubMed ID: 28255276
[TBL] [Abstract][Full Text] [Related]
8. Novel function of MDA-9/Syntenin (SDCBP) as a regulator of survival and stemness in glioma stem cells.
Talukdar S; Das SK; Pradhan AK; Emdad L; Shen XN; Windle JJ; Sarkar D; Fisher PB
Oncotarget; 2016 Aug; 7(34):54102-54119. PubMed ID: 27472461
[TBL] [Abstract][Full Text] [Related]
9. Targeting NEK2 attenuates glioblastoma growth and radioresistance by destabilizing histone methyltransferase EZH2.
Wang J; Cheng P; Pavlyukov MS; Yu H; Zhang Z; Kim SH; Minata M; Mohyeldin A; Xie W; Chen D; Goidts V; Frett B; Hu W; Li H; Shin YJ; Lee Y; Nam DH; Kornblum HI; Wang M; Nakano I
J Clin Invest; 2017 Aug; 127(8):3075-3089. PubMed ID: 28737508
[TBL] [Abstract][Full Text] [Related]
10. Ribosomal S6 protein kinase 4 promotes resistance to EZH2 inhibitors in glioblastoma.
Pang F; Zhang L; Li M; Yi X; Wang Y; Yang P; Wen B; Jiang J; Teng Y; Yang X; Chen L; Xu J; Wang L
Cancer Gene Ther; 2023 Dec; 30(12):1636-1648. PubMed ID: 37726387
[TBL] [Abstract][Full Text] [Related]
11. Repurposing FDA approved drugs inhibiting mitochondrial function for targeting glioma-stem like cells.
Datta S; Sears T; Cortopassi G; Woolard K; Angelastro JM
Biomed Pharmacother; 2021 Jan; 133():111058. PubMed ID: 33378970
[TBL] [Abstract][Full Text] [Related]
12. lncRNA TUG1 inhibits the cancer stem cell‑like properties of temozolomide‑resistant glioma cells by interacting with EZH2.
Cao Y; Chai W; Wang Y; Tang D; Shao D; Song H; Long J
Mol Med Rep; 2021 Jul; 24(1):. PubMed ID: 34036375
[TBL] [Abstract][Full Text] [Related]
13. EZH2 interacts with HP1BP3 to epigenetically activate WNT7B that promotes temozolomide resistance in glioblastoma.
Yu T; Zhou F; Tian W; Xu R; Wang B; Zeng A; Zhou Z; Li M; Wang Y; Zhang J
Oncogene; 2023 Feb; 42(6):461-470. PubMed ID: 36517590
[TBL] [Abstract][Full Text] [Related]
14. EZH2 is a potential prognostic predictor of glioma.
Chen YN; Hou SQ; Jiang R; Sun JL; Cheng CD; Qian ZR
J Cell Mol Med; 2021 Jan; 25(2):925-936. PubMed ID: 33277782
[TBL] [Abstract][Full Text] [Related]
15. Tanshinone IIA inhibits the growth, attenuates the stemness and induces the apoptosis of human glioma stem cells.
Yang L; Guo H; Dong L; Wang L; Liu C; Wang X
Oncol Rep; 2014 Sep; 32(3):1303-11. PubMed ID: 24970314
[TBL] [Abstract][Full Text] [Related]
16. Isoliquiritigenin inhibits the proliferation and induces the differentiation of human glioma stem cells.
Lin Y; Sun H; Dang Y; Li Z
Oncol Rep; 2018 Feb; 39(2):687-694. PubMed ID: 29251326
[TBL] [Abstract][Full Text] [Related]
17. TGF-β-activated lncRNA LINC00115 is a critical regulator of glioma stem-like cell tumorigenicity.
Tang J; Yu B; Li Y; Zhang W; Alvarez AA; Hu B; Cheng SY; Feng H
EMBO Rep; 2019 Dec; 20(12):e48170. PubMed ID: 31599491
[TBL] [Abstract][Full Text] [Related]
18. A novel drug conjugate, NEO212, targeting proneural and mesenchymal subtypes of patient-derived glioma cancer stem cells.
Jhaveri N; Agasse F; Armstrong D; Peng L; Commins D; Wang W; Rosenstein-Sisson R; Vaikari VP; Santiago SV; Santos T; Chen L; Schönthal AH; Chen TC; Hofman FM
Cancer Lett; 2016 Feb; 371(2):240-50. PubMed ID: 26683773
[TBL] [Abstract][Full Text] [Related]
19. No Significant Cytotoxic Effect of the EZH2 Inhibitor Tazemetostat (EPZ-6438) on Pediatric Glioma Cells with Wildtype Histone 3 or Mutated Histone 3.3.
Wiese M; Schill F; Sturm D; Pfister S; Hulleman E; Johnsen SA; Kramm CM
Klin Padiatr; 2016 Apr; 228(3):113-7. PubMed ID: 27135271
[TBL] [Abstract][Full Text] [Related]
20. ATRX/EZH2 complex epigenetically regulates FADD/PARP1 axis, contributing to TMZ resistance in glioma.
Han B; Meng X; Wu P; Li Z; Li S; Zhang Y; Zha C; Ye Q; Jiang C; Cai J; Jiang T
Theranostics; 2020; 10(7):3351-3365. PubMed ID: 32194873
[No Abstract] [Full Text] [Related]
[Next] [New Search]
